194 related articles for article (PubMed ID: 15728323)
1. Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barré syndrome?
Berciano J; Illa I
Neurology; 2005 Feb; 64(4):766-7; author reply 766-7. PubMed ID: 15728323
[No Abstract] [Full Text] [Related]
2. Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barre syndrome?
Kuwabara S; Ogawara K; Misawa S; Koga M; Mori M; Hiraga A; Kanesaka T; Hattori T; Yuki N
Neurology; 2004 Aug; 63(3):529-33. PubMed ID: 15304587
[TBL] [Abstract][Full Text] [Related]
3. A family with Campylobacter enteritis: anti-GD1a antibody with/without Guillain-Barré syndrome.
Hirano M; Kusunoki S; Asai H; Tonomura Y; Morita D; Ueno S
Neurology; 2003 May; 60(10):1719-20. PubMed ID: 12771281
[No Abstract] [Full Text] [Related]
4. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome.
Jacobs BC; Koga M; van Rijs W; Geleijns K; van Doorn PA; Willison HJ; Yuki N
J Neuroimmunol; 2008 Feb; 194(1-2):181-90. PubMed ID: 18178257
[TBL] [Abstract][Full Text] [Related]
5. The relationship of Campylobacter jejuni infection and the development of Guillain-Barré syndrome.
Tsang RS
Curr Opin Infect Dis; 2002 Jun; 15(3):221-8. PubMed ID: 12015454
[TBL] [Abstract][Full Text] [Related]
6. [Guillain-Barre syndrome and Campylobacter].
Engberg JH
Ugeskr Laeger; 2002 Dec; 164(50):5905-8. PubMed ID: 12553106
[No Abstract] [Full Text] [Related]
7. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome.
Bowes T; Wagner ER; Boffey J; Nicholl D; Cochrane L; Benboubetra M; Conner J; Furukawa K; Furukawa K; Willison HJ
Infect Immun; 2002 Sep; 70(9):5008-18. PubMed ID: 12183547
[TBL] [Abstract][Full Text] [Related]
8. Guillain Barré Syndrome is induced in Non-Obese Diabetic (NOD) mice following Campylobacter jejuni infection and is exacerbated by antibiotics.
St Charles JL; Bell JA; Gadsden BJ; Malik A; Cooke H; Van de Grift LK; Kim HY; Smith EJ; Mansfield LS
J Autoimmun; 2017 Feb; 77():11-38. PubMed ID: 27939129
[TBL] [Abstract][Full Text] [Related]
9. Is Campylobacter lipopolysaccharide bearing a GD3 epitope essential for the pathogenesis of Guillain-Barré syndrome?
Yuki N; Koga M; Hirata K
Acta Neurol Scand; 2000 Aug; 102(2):132-4. PubMed ID: 10949532
[TBL] [Abstract][Full Text] [Related]
10. Anti-ganglioside antibodies in patients with Guillain-Barré syndrome and Campylobacter jejuni infection.
Rees JH; Gregson NA; Hughes RA
J Infect Dis; 1995 Aug; 172(2):605-6. PubMed ID: 7622918
[No Abstract] [Full Text] [Related]
11. [Campylobacter jejuni enteritis and Guillain-Barré syndrome].
Yuki N
Rinsho Byori; 1999 Aug; 47(8):713-8. PubMed ID: 10511801
[TBL] [Abstract][Full Text] [Related]
12. Prognosis in the acute motor axonal form of Guillain-Barré syndrome.
Gabriel CM
J Neurol Neurosurg Psychiatry; 2005 May; 76(5):622. PubMed ID: 15834016
[No Abstract] [Full Text] [Related]
13. Hyperreflexia in axonal Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis.
Kuwabara S; Nakata M; Sung JY; Mori M; Kato N; Hattori T; Koga M; Yuki N
J Neurol Sci; 2002 Jul; 199(1-2):89-92. PubMed ID: 12084449
[TBL] [Abstract][Full Text] [Related]
14. Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies.
Prendergast MM; Moran AP
J Endotoxin Res; 2000; 6(5):341-59. PubMed ID: 11521055
[TBL] [Abstract][Full Text] [Related]
15. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies.
Ho TW; Mishu B; Li CY; Gao CY; Cornblath DR; Griffin JW; Asbury AK; Blaser MJ; McKhann GM
Brain; 1995 Jun; 118 ( Pt 3)():597-605. PubMed ID: 7600081
[TBL] [Abstract][Full Text] [Related]
16. [A case of Guillain-Barré syndrome after Campylobacter jejuni enterocolitis: anti-ganglioside antibody levels with or without Guillain-Barré syndrome].
Watanabe H; Shindo K; Nakamura Y; Nagamatsu M; Shiozawa Z; Kusunoki S
Rinsho Shinkeigaku; 2001 Sep; 41(9):625-7. PubMed ID: 11968750
[TBL] [Abstract][Full Text] [Related]
17. Preceding infections and anti-ganglioside antibodies in patients with Guillain-Barré syndrome: a single centre prospective case-control study.
Sinha S; Prasad KN; Jain D; Pandey CM; Jha S; Pradhan S
Clin Microbiol Infect; 2007 Mar; 13(3):334-7. PubMed ID: 17391394
[TBL] [Abstract][Full Text] [Related]
18. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome.
Yuki N
J Infect Dis; 1997 Dec; 176 Suppl 2():S150-3. PubMed ID: 9396700
[TBL] [Abstract][Full Text] [Related]
19. T cell recognition of a non-protein antigen preparation of Campylobacter jejuni in patients with Guillain-Barré syndrome.
Cooper JC; Hughes S; Ben-Smith A; Savage CO; Winer JB
J Neurol Neurosurg Psychiatry; 2002 Mar; 72(3):413-4. PubMed ID: 11861714
[No Abstract] [Full Text] [Related]
20. Recognition characteristics of monoclonal antibodies that are cross-reactive with gangliosides and lipooligosaccharide from Campylobacter jejuni strains associated with Guillain-Barré and Fisher syndromes.
Houliston RS; Yuki N; Hirama T; Khieu NH; Brisson JR; Gilbert M; Jarrell HC
Biochemistry; 2007 Jan; 46(1):36-44. PubMed ID: 17198373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
